April 17, 2014 2:43 PM ET


Company Overview of Angiochem Inc.

Company Overview

Angiochem Inc. is a clinical-stage biotechnology company developing drugs to treat brain diseases and brain-related disorders. Its products are used to treat oncology, pain, type II diabetes and obesity, Parkinson's disease, neurodegenerative and metabolic diseases, pain, and other central nervous system related disorders. The company develops products based on its engineered peptide compound (EPiC) technology. Angiochem Inc. was founded in 2003 and is based in Montreal, Canada.

201 President-Kennedy Avenue

Suite PK-R220

Montreal, QC H2X 3Y7


Founded in 2003





Key Executives for Angiochem Inc.

Age: 68
Acting Head of Finance
Vice President of Development
Director of Research
Director of Corporate Development
Compensation as of Fiscal Year 2013.

Angiochem Inc. Key Developments

Angiochem Demonstrates Peptide Antibody Conjugate That Successfully Crosses the Blood Brain Barrier and Increases Survival in HER-2 Positive Brain Tumors

Angiochem announced that its peptide-antibody conjugate, ANG4043 successfully crosses the BBB, reduces tumor size and significantly increases survival in mice with intracranial HER2-positive brain tumors. These results underscore the potential for development of novel antitumor therapeutics for neuro-oncology indications. The data presentation revealed that the company's technology has been successfully applied to monoclonal antibodies (mAbs) for creation of brain-penetrant antibody conjugates of anti-Human Epidermal Growth Factor Receptor 2 (HER2). Angiochem researchers described the ANG4043 preclinical results, including: In vivo, in mice that were implanted intracranially with HER2+ human breast tumor cells (BT-474), it was observed: ANG4043 crosses the BBB and reaches the tumor using near-infrared imaging, where a strong signal is observed in brain following IV administration of fluorescent ANG4043, but not of fluorescent anti-HER2. Reduction in tumor size correlating with increased survival. In vitro, ANG4043 binding affinity for HER2 receptor and anti-proliferative properties were similar to the native, unconjugated mAb.

Angiochem Inc. Presents at 2013 Therapeutic Area Partnerships Conference, Nov-19-2013 01:30 PM

Angiochem Inc. Presents at 2013 Therapeutic Area Partnerships Conference, Nov-19-2013 01:30 PM. Venue: One Avenue De Lafayette, Boston, MA 02111, United States.

Angiochem Announces Results from Phase II Breast Cancer Study

Angiochem has announced complete analysis results from a Phase II clinical study with ANG1005, a novel paclitaxel-peptide drug conjugate, in breast cancer patients with brain metastasis. Angiochem presented the Phase II ITT analysis with ANG1005 in 80 HER2-positive and HER2-negative breast cancer. patients with brain metastases. Two doses, 650mg/m2 (n=13) and 550mg/m2 (n=67), were evaluated for intracranial anti-tumor responses including response rate, progression-free survival (PFS) and overall survival (OS) as well as safety and tolerability. In the study, ANG1005 was generally safe and well-tolerated, and demonstrated an adverse event profile consistent with conventional taxane therapy in both HER2-positive and HER2-negative cohorts at both dose levels studied. In addition, patients in both the HER2-positive and HER2-negative populations experienced anti-tumor responses including up to 14 patients with intracranial partial responses (PR), 35 patients with stable disease(SD) and six months overall survival in up to 85%. ANG1005 was generally safe and well-tolerated with taxane-related adverse events including neutropenia, fatigue, peripheral neuropathy and mucosal inflammation. HER2-positive patients (n=36) achieved PR's (9, 25%) and SD (18, 50%) thereby demonstrating disease control in 75% of those patients. In addition, at the dose level of 550 mg/m2, three month PFS was 71% with a median PFS of 128 days and OS at six months of 82%. Her2-negative patients (n=44) achieved PR's (5, 11%) and SD (17, 32%) thereby demonstrating disease control in 50% of those patients. In addition, at the dose level of 550 mg/m2, three months of PFS was 35% with a median PFS of 84 days and OS at six months of 60%. Based on these results, Angiochem will advance ANG1005 into further clinical development including a Phase II clinical study in patients with recurrent high grade gliomas which began enrolling in October 2013 and a Phase II clinical study in HER2-positive breast cancer patients with brain metastases which will begin enrolling in the first quarter of 2014.

Similar Private Companies By Industry

Company Name Region
Briana Bio Tech, Inc. Americas
PerkinElmer BioSignal, Inc. Americas
CellFor Inc. Americas
Chlorion Pharma, Inc. Americas
Fedora Pharmaceuticals Inc. Americas

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Angiochem Inc., please visit www.angiochem.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.